‘Urgent Need’ To Revisit Australia’s Gestational Diabetes Criteria

‘Urgent Need’ To Revisit Australia’s Gestational Diabetes Criteria
(Dina2001/iStock)
Marina Zhang
2/6/2022
Updated:
2/7/2022
A study conducted by the University of Queensland has called for an “urgent need” to revisit the diagnostic criteria for gestational diabetes mellitus (GDM) diagnosis, encouraging the review of the one-step diagnosis recommended by the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) and practiced widely in Australia.
Australia currently undertakes the one-step diagnosis where a fasting patient undergoes a 75-gram, oral glucose tolerance test with measurements of blood glucose concentrations taken at the first hour and the second hour after administration of the glucose solution. The result would be considered abnormal if any one measurement, the fasting blood glucose concentration; taken prior to administration or the 1 hour, or 2-hour result is above a specified threshold.

The two-step diagnostic criteria is recommended by the Australasian Diabetes in Pregnancy Society and entails non-fasting patients ingesting a 50-g oral glucose solution followed by a 1-hour glucose measurement.

If the blood glucose level after 1 hour is over 200mg/dL, then no further testing is needed, and a diagnosis of GDM is made. If the blood level falls been 130mg/dL and 200mg/dL, then the patient undergoes a fasting 3-hour glucose tolerance test and GDM is diagnosed if two or more hourly glucose measurements are above specified thresholds.

The one-step criteria often results in a greater proportion amount of diagnosis as compared to the two-step approach, however, the author argued that the two-step approach results in a smaller proportion of diagnosis because there are variations in individuals with hyperglycaemia, a risk factor for GDM whereas for the one-step criteria, “women with even a mildly elevated measure of any of the three glucose measurements” will be diagnosed with GDM, thereby leading to possible false positives in diagnosis.

The Royal Australian College of General Practitioners (RACGP) had objected (pdf) to the adoption of the one-step process, arguing that “there is a lack of evidence that the subset of women” identified by the one-step approach, who would have been considered normal by the two-step approach, benefited from the increased interventions and monitoring following the diagnosis.
The research team, led by Jenny Doust from the University of Queensland used a 2021 study conducted by the Center for Health Research in Hawaii to argue for their case, for the trial women were randomly assigned to the one-step or two-step GDM criteria and resulted in 16.5 percent of women being diagnosed in the one-step group and 8.5 in the two-step group and treated based on the diagnosis.

However, the research did not find much difference in the clinical results between the two groups as both had a similar proportion of large-for-gestational infants, preeclampsia, hypertension, and other risk factors for GDM.

“A significant proportion of the women who were assigned to the one-step arm of the trial underwent a two-step process. This reflects the real-world preferences of the women and clinicians who participated in the trial,” Doust and colleagues wrote.

The authors wrote that the broadened proportion of women being diagnosed can introduce potential for harm, including life disruptions for the women diagnosed as well as “a risk of more invasive forms of delivery in these women, and potential harms to the infant from restricted diets and the use of insulin,” supported by research conducted at the Kaiser Permanente Baldwin Park Medical Center in the U.S.

Since COVID-19, the two-step approach was introduced in Australia to prevent community infections (pdf), a 2020 study led by the University of Queensland showed that this may reduce the overall diagnosis frequency in Australia by 25 percent.

Currently, there still are ongoing trials aiming at comparing the two approaches, however, the authors concluded that there are “significant risks of harms and considerable burdens to women and health care systems” and called for a revisit of the diagnostic criteria for GDM in Australia.

Marina Zhang is a health writer for The Epoch Times, based in New York. She mainly covers stories on COVID-19 and the healthcare system and has a bachelors in biomedicine from The University of Melbourne. Contact her at [email protected].
Related Topics